Division of Pulmonary and Critical Care, Washington University School of Medicine, 4523 Clayton Avenue, Campus Box 8052, St Louis, MO 63110, USA.
Clin Chest Med. 2017 Dec;38(4):667-675. doi: 10.1016/j.ccm.2017.07.008. Epub 2017 Sep 1.
Despite advances in immunosuppression over the past 25 years, acute cellular rejection remains a common complication early after lung transplantation. Although acute cellular rejection has often not resulted in clinical signs or symptoms of allograft dysfunction, it has been widely recognized as a strong independent risk factor for the development of chronic rejection, emphasizing its clinical significance. In recent years, the role of humoral immunity in lung rejection has been increasingly appreciated, and antibody-mediated rejection is now recognized as a form of rejection that may result in allograft failure.
尽管过去 25 年来免疫抑制方面取得了进步，但急性细胞排斥仍然是肺移植后早期的常见并发症。尽管急性细胞排斥通常不会导致移植物功能障碍的临床体征或症状，但它已被广泛认为是慢性排斥发展的一个强有力的独立危险因素，凸显了其临床意义。近年来，体液免疫在肺排斥中的作用越来越受到重视，抗体介导的排斥现在被认为是一种可能导致移植物衰竭的排斥形式。
